Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer - Expert Commentary
The trial showed a pathologic complete response rate of 44.8% (13/29 patients), with manageable safety, and 90% (26/29) of patients proceeded to cystectomy. Radiologic evaluation revealed an overall response rate of 28% and clinical benefit rate of 88%, with disease progression observed in only 12% of cases. Molecular analyses demonstrated that mutational patterns, tumor mutation burden, and homologous recombination deficiency status remained stable throughout treatment and did not predict clinical outcomes. However, significant transcriptomic changes were observed, particularly in resistant tumors, with a shift toward stromal phenotypes and increased expression of epithelial-mesenchymal transition signatures. Additionally, an increase in circulating CD4+ CD27- CD28- T cells (effector memory T cells) was noted among responders, becoming statistically significant at follow-up.
Given the high prevalence of germline mutations in DNA repair genes in patients with bladder cancer, this important study shows that the combination of neoadjuvant durvalumab and olaparib demonstrates meaningful therapeutic activity in urothelial bladder cancer. Interestingly, resistance mechanisms appear to be driven by transcriptional adaptations rather than the emergence of new mutations, suggesting that targeting transcriptional pathways might be a potential strategy to overcome resistance. These findings provide important insights into bladder cancer biology and treatment response, potentially informing the design of future clinical trials combining immunotherapy and PARP inhibitors.
Written by: Bishoy M. Faltas, MD, Chief Research Officer, Englander Institute for Precision Medicine, Gellert Family - John P. Leonard, MD, Research Scholar, Associate Professor of Medicine, Cell and Developmental Biology, Weill Cornell Medicine, New York- Presbyterian Hospital, NY
References:
Read the Abstract